Meghamsh Kanuparthy

6PUBLICATIONS
11CO-AUTHORS
Infectious diseasesCardiology (incl. cardiovascular diseases)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 12, 2026
Cellular and Molecular Mechanisms of SARS-CoV-2 Spike Protein-Induced Endothelial Dysfunction.

Kelsey C Muir, Dwight D Harris, Meghamsh Kanuparthy

|Dec 18, 2025
Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling.

Kelsey C Muir, Christopher Stone, Riya Reddy

|Jul 03, 2025
Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction.

Meghamsh Kanuparthy, Dwight D Harris, Mark Broadwin

|Mar 13, 2025
Sex-Specific Improvements in Myocardial Function and Angiogenesis with SGLT-2 Inhibitor Canagliflozin in a Swine Model of Metabolic Syndrome.

Dwight D Harris, Mark Broadwin, Christopher Stone

|Dec 12, 2024
Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.

Christopher Stone, Dwight D Harris, Mark Broadwin

|Mar 28, 2024
Proteomic Profiling of SGLT-2 Inhibitor Canagliflozin in a Swine Model of Chronic Myocardial Ischemia.

Dwight D Harris, Sharif A Sabe, Mark Broadwin

Pageof 1